|
1
|
Uribe R and Jay D: A review of actin
binding proteins: new perspectives. Mol Biol Rep. 36:121–125. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
dos Remedios CG, Chhabra D, Kekic M, et
al: Actin binding proteins: regulation of cytoskeletal
microfilaments. Physiol Rev. 83:433–473. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Winder SJ and Ayscough KR: Actin-binding
proteins. J Cell Sci. 118:651–654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dominguez R: Actin-binding proteins - a
unifying hypothesis. Trends Biochem Sci. 29:572–578. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Janmey PA and Chaponnier C: Medical
aspects of the actin cytoskeleton. Curr Opin Cell Biol. 7:111–117.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pollard TD and Borisy GG: Cellular
motility driven by assembly and disassembly of actin filaments.
Cell. 112:453–465. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li GH, Arora PD, Chen Y, McCulloch CA and
Liu P: Multifunctional roles of gelsolin in health and diseases.
Med Res Rev. 32:999–1025. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shieh DB, Chen IW, Wei TY, et al: Tissue
expression of gelsolin in oral carcinogenesis progression and its
clinicopathological implications. Oral Oncol. 42:599–606. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mullauer L, Fujita H, Ishizaki A and
Kuzumaki N: Tumor-suppressive function of mutated gelsolin in
ras-transformed cells. Oncogene. 8:2531–2536. 1993.PubMed/NCBI
|
|
10
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics. 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
12
|
Nomura H, Uzawa K, Ishigami T, et al:
Clinical significance of gelsolin-like actin-capping protein
expression in oral carcinogenesis: an immunohistochemical study of
premalignant and malignant lesions of the oral cavity. BMC Cancer.
8:392008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Petersen PE: Oral cancer prevention and
control - the approach of the World Health Organization. Oral
Oncol. 45:454–460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tsantoulis PK, Kastrinakis NG, Tourvas AD,
Laskaris G and Gorgoulis VG: Advances in the biology of oral
cancer. Oral Oncol. 43:523–534. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
da Silva SD, Ferlito A, Takes RP, et al:
Advances and applications of oral cancer basic research. Oral
Oncol. 47:783–791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sciubba JJ: Oral cancer. The importance of
early diagnosis and treatment. Am J Clin Dermatol. 2:239–251. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ayscough KR: In vivo functions of
actin-binding proteins. Curr Opin Cell Biol. 10:102–111. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tanaka M, Mullauer L, Ogiso Y, et al:
Gelsolin: a candidate for suppressor of human bladder cancer.
Cancer Res. 55:3228–3232. 1995.PubMed/NCBI
|
|
19
|
Noske A, Denkert C, Schober H, et al: Loss
of Gelsolin expression in human ovarian carcinomas. Eur J Cancer.
41:461–469. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dosaka-Akita H, Hommura F, Fujita H, et
al: Frequent loss of gelsolin expression in non-small cell lung
cancers of heavy smokers. Cancer Res. 58:322–327. 1998.PubMed/NCBI
|
|
21
|
Winston JS, Asch HL, Zhang PJ, Edge SB,
Hyland A and Asch BB: Downregulation of gelsolin correlates with
the progression to breast carcinoma. Breast Cancer Res Treat.
65:11–21. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim JH, Choi YK, Kwon HJ, Yang HK, Choi JH
and Kim DY: Downregulation of gelsolin and retinoic acid receptor
beta expression in gastric cancer tissues through histone
deacetylase 1. J Gastroenterol Hepatol. 19:218–224. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ni XG, Zhou L, Wang GQ, et al: The
ubiquitin-proteasome pathway mediates gelsolin protein
downregulation in pancreatic cancer. Mol Med. 14:582–589. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shieh DB, Godleski J, Herndon JE II, et
al: Cell motility as a prognostic factor in Stage I nonsmall cell
lung carcinoma: the role of gelsolin expression. Cancer. 85:47–57.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liao CJ, Wu TI, Huang YH, et al:
Overexpression of gelsolin in human cervical carcinoma and its
clinicopathological significance. Gynecol Oncol. 120:135–144. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Silacci P, Mazzolai L, Gauci C,
Stergiopulos N, Yin HL and Hayoz D: Gelsolin superfamily proteins:
key regulators of cellular functions. Cell Mol Life Sci.
61:2614–2623. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
An JH, Kim JW, Jang SM, Kim CH, Kang EJ
and Choi KH: Gelsolin negatively regulates the activity of tumor
suppressor p53 through their physical interaction in
hepatocarcinoma HepG2 cells. Biochem Biophys Res Commun. 412:44–49.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Koya RC, Fujita H, Shimizu S, et al:
Gelsolin inhibits apoptosis by blocking mitochondrial membrane
potential loss and cytochrome c release. J Biol Chem.
275:15343–15349. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kusano H, Shimizu S, Koya RC, et al: Human
gelsolin prevents apoptosis by inhibiting apoptotic mitochondrial
changes via closing VDAC. Oncogene. 19:4807–4814. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kwiatkowski DJ: Functions of gelsolin:
motility, signaling, apoptosis, cancer. Curr Opin Cell Biol.
11:103–108. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sakurai N and Utsumi T: Posttranslational
N-myristoylation is required for the anti-apoptotic activity of
human tGelsolin, the C-terminal caspase cleavage product of human
gelsolin. J Biol Chem. 281:14288–14295. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Azuma T, Koths K, Flanagan L and
Kwiatkowski D: Gelsolin in complex with phosphatidylinositol
4,5-bisphosphate inhibits caspase-3 and-9 to retard apoptotic
progression. J Biol Chem. 275:3761–3766. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Galluzzi L and Kroemer G: Mitochondrial
apoptosis without VDAC. Nat Cell Biol. 9:487–489. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Baines CP, Kaiser RA, Sheiko T, Craigen WJ
and Molkentin JD: Voltage-dependent anion channels are dispensable
for mitochondrial-dependent cell death. Nat Cell Biol. 9:550–555.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ke H, Parron VI, Reece J, Zhang JY,
Akiyama SK and French JE: BCL2 inhibits cell adhesion, spreading,
and motility by enhancing actin polymerization. Cell Res.
20:458–469. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
De Corte V, Bruyneel E, Boucherie C,
Mareel M, Vandekerckhove J and Gettemans J: Gelsolin-induced
epithelial cell invasion is dependent on Ras-Rac signaling. EMBO J.
21:6781–6790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Azuma T, Witke W, Stossel TP, Hartwig JH
and Kwiatkowski DJ: Gelsolin is a downstream effector of rac for
fibroblast motility. EMBO J. 17:1362–1370. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Radwanska A, Litwin M, Nowak D, et al:
Overexpression of lumican affects the migration of human colon
cancer cells through up-regulation of gelsolin and filamentous
actin reorganization. Exp Cell Res. 318:2312–2323. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Litwin M, Nowak D, Mazur AJ, Baczynska D,
Mannherz HG and Malicka-Blaszkiewicz M: Gelsolin affects the
migratory ability of human colon adenocarcinoma and melanoma cells.
Life Sci. 90:851–861. 2012. View Article : Google Scholar : PubMed/NCBI
|
